Salute e Benessere

Evaxion to present new biomarker data for AI-designed personalized cancer…

New biomarker and immune data from the ongoing phase 2 trial with EVX-01 will be presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting The data will be the latest of many additions to EVX-01’s strong data packageTwo-year clinical efficacy data from the trial will be presented at the European Society for Medical Oncology (ESMO) 2025 congress on October 17, 2025COPENHAGEN, Denmark, October 3, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a...
Nasdaq GlobeNewswire
03/10/2025

Animal Health Market Size to Reach US$ 119.44 Bn by 2033, Driven by Rising Pet…

Get a Free Sample PDF Brochure of the Report (Use Corporate Email ID for a Quick Response): https://www.datamintelligence.com/download-sample/animal-health-market Get a Free Sample PDF Brochure of the Report (Use Corporate Email ID for a Quick Response): https://www.datamintelligence.com/download-sample/animal-health-market Browse in-depth TOC on "Oral Contraceptive Pills Market" 62 – Tables 55 – Figures 180 – Pages By product type, the biologics segment from product...
PR Newswire
03/10/2025

Active Pharmaceutical Ingredients (API) Market to Surpass US$ 428.5 Billion by…

Digital & AI-driven transformation – Artificial intelligence, machine learning, and digital twins are being integrated into R&D and manufacturing. These tools optimize synthesis pathways, predict yields, reduce time-to-market, and enable "smart API factories" with real-time quality monitoring. Digital & AI-driven transformation – Artificial intelligence, machine learning, and digital twins are being integrated into R&D and manufacturing. These tools optimize synthesis…
PR Newswire
03/10/2025

Duodenoscopes Market 2025-2030 Forecasts shows 5.5% CAGR, Says Mordor…

Advances in Imaging and AI Advances in Imaging and AI New imaging technologies and AI tools are improving accuracy, enabling earlier detection and fewer missed diagnoses. Flexible scope designs also enhance outcomes in complex cases. These innovations are driving hospitals toward premium systems and raising standards of gastrointestinal care. Growing Preference for Minimally Invasive ERCP Healthcare systems are shifting toward minimally invasive options that cut recovery time and...
PR Newswire
03/10/2025

COSRX Makes History as First Korean Skincare and Haircare Brand to Sponsor Paris…

COSRX's role as an official backstage sponsor of Paris Fashion Week's September main season is a milestone in itself. Traditionally, these shows rely on in-house beauty lines or major global affiliates, leaving little room for outside brands. Verified records confirm that this marks the first time in the 53-year history of Paris Fashion Week that a Korean brand has officially partnered backstage for the September main season. More than a sponsorship, it signals a cultural and industry…
PR Newswire
03/10/2025

Cosentino launches its new Éclos® brand: an innovative generation of mineral…

"Since our founding, we have been committed to leading innovation rather than following trends. Just as we did with Silestone®, Dekton®, and most recently with Hybriq+® technology for Silestone®. Éclos® involves a new turning point for our industry, an evolution that responds to real market needs and anticipates the future," says Pilar Cosentino, Cosentino Group CEO. "Since our founding, we have been committed to leading innovation rather than following trends. Just as we did…
PR Newswire
03/10/2025

Mediso installs true theranostic TheraMAX SPECT/CT at Heidelberg University…

"The TheraMAX expands the imaging capabilities of our department for radioligand therapy. We treat patients with a wide range of novel radiopharmaceuticals labelled with 177Lu or 225Ac, some of them as part of clinical trials for developing improved and more individualized patient care. In addition, the TheraMAX supports our department by increasing the capacity of our department for 99mTc-PSMA scans for radioligand therapy inclusion" said Professor Dr. Clemens Kratochwil, lead…
PR Newswire
03/10/2025

Zinzino AB (publ.): Preliminary Sales Report Q3 2025

Revenue in Zinzino's sales markets increased by 54 % in the third quarter of 2025 compared with the same period last year and amounted to SEK 777.3 (504.4) million. Total revenues in the Group increased by 48% in the third quarter and amounted to SEK 786.7 (532.8) million. Revenue in Zinzino's sales markets increased by 54 % in the third quarter of 2025 compared with the same period last year and amounted toSEK 777.3(504.4) million. Total revenues in the Group increased by 48% in the third...
PR Newswire
03/10/2025

The Department of Clinical and Molecular Medicine of Sapienza University of…

Following a successful proof-of-concept using model cells, the collaboration now moves into a clinical phase. Blood samples from lung cancer patients will be collected at Sant'Andrea Hospital in Rome and processed at DMCM where Tethis' See.d instrument has been installed. The instrument will produce cytology slides containing cells, including CTCs. These slides will then be sent to Tethis, where they will be stained with Takis' HER3-specific antibody, enabling the identification of HER3-positive…
PR Newswire
03/10/2025

Appointment of Marc Le Bozec as Interim CEO

Appointment of Marc Le Bozec as Interim CEO Nantes, October 3, 2025, 8:00 a.m. CET – OSE Immunotherapeutics (ISIN: FR0012127173; Mnemonic: OSE)announces the termination of the position as chief executive officer of Mr. Nicolas Poirier and the appointment of Mr. Marc Le Bozec as interim CEO, as decided yesterday by the Board of Directors.The Board of Directors has commenced a formal search for a new permanent Chief Executive Officer.The Board of Directors has empowered Marc Le Bozec...
Nasdaq GlobeNewswire
03/10/2025

A New Era of Modest Elegance: Royals Unveil Three Muslim-Friendly Lifestyle…

The three brands reflect the spirit of modest elegance, each carrying the unique vision of its founder: The three brands reflect the spirit of modest elegance, each carrying the unique vision of its founder: NARA, founded byYang Mulia Tengku Khairul Adena, embodies timeless luxury and sophistication. With a focus on handbags and cosmetics, NARA blends heritage and modernity to create statement pieces. Inspired by her vision to empower women with confidence and individuality, the brand...
PR Newswire
03/10/2025

FDA approves Roche’s Tecentriq plus lurbinectedin as first-line maintenance…

Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal phase III IMforte study 1 First and only combination therapy for the first-line maintenance treatment of ES-SCLC, which is critical to help address the high rate of relapse in ES-SCLC 2 Regimen recommended in National Comprehensive Cancer Network® Guidelines for SCLC* 3 Basel, 3 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug...
Nasdaq GlobeNewswire
03/10/2025

Santhera Announces Approval in Canada for AGAMREE® (Vamorolone) as a Treatment…

Health Canada approved AGAMREE for the treatment of Duchenne muscular dystrophy in patients aged 4 years and olderThis approval makes AGAMREE the first and only approved therapy for DMD in Canada Pratteln, Switzerland, October 3, 2025 –Santhera Pharmaceuticals (SIX: SANN) today notes that Health Canada has approved AGAMREE® (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 4 years and older following Priority Review, marking the first approved...
Nasdaq GlobeNewswire
03/10/2025

Change in the Roche Board of Directors

Dr. Süssmuth Dyckerhoff has served on the Board of Directors since March 2016.Roche Chairman Severin Schwan: "Claudia’s profound knowledge of the healthcare industry and her deep understanding of international market dynamics, particularly in Asia, have resulted in significant contributions to the success of Roche. On behalf of the Board, I would like to sincerely thank Claudia for her dedication to Roche over the past decade and wish her all the best for the future.” About Roche...
Nasdaq GlobeNewswire
03/10/2025

MedHub-AI Announces National Reimbursement Approval in Japan for AutocathFFR™

Addressing a Critical Healthcare Need Addressing a Critical Healthcare Need Coronary artery disease is the number one cause of morbidity and mortality worldwide, including inJapanwhere the burden of cardiovascular disease continues to rise. The introduction of AI-driven, non-invasive physiology represents an important advancement for both clinicians and patients by supporting evidence-based decision-making, reducing procedural complexity, and potentially lowering overall healthcare...
PR Newswire
03/10/2025

Graves' Orbitopathy Market to Exhibit Growth at a CAGR of 19.8% During the…

Graves' Orbitopathy Market Summary Graves' Orbitopathy Market Summary Discover the new Graves' orbitopathy treatment @Graves' Orbitopathy Treatment Market Key Factors Driving the Growth of the Graves' Orbitopathy Market Rising Graves' Orbitopathy Prevalence According to DelveInsight analysis, there were approximately 1.4 million diagnosed prevalent cases of Graves' orbitopathy in the 7MM in 2024, with the number projected to rise by 2034. In 2024, the US reported that...
PR Newswire
02/10/2025

Oxurion Receives Transparency Notification from Atlas Special Opportunities II…

Leuven, BELGIUM – October 2, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received transparency notification as follows: Oxurion received a transparency notification on October 2, 2025, from Atlas Special Opportunities II…
Actusnews Wire
02/10/2025

HELFIE AI BOLSTERS INNOVATION AND MEDICAL EXPERTISE WITH NEW CHIEF MEDICAL…

Habash co-founded HipaaChat and served as Chief Medical Officer of Everbridge, where she helped scale secure messaging and telemedicine platforms to over 1,500 hospitals while collaborating with leading technology companies like Apple, Amazon, and Verizon to modernize healthcare communications. At Microsoft Healthcare, she partnered with their healthcare team to lead a large AI initiative, generating multi-disease retinal algorithms for autonomous diagnosis of eye conditions and built a global…
PR Newswire
02/10/2025

Aid cannot wait - Hydrachem urges global action to break barriers to clean water

Nicolas Barbieri, Chief Commercial Officer at Hydrachem, commented: Nicolas Barbieri, Chief Commercial Officer atHydrachem, commented: "A global commitment to humanitarian aid is meaningless if we cannot get what is needed into the hands of vulnerable communities. In every crisis we see the same pattern: water supplies are destroyed or contaminated, disease spreads and aid agencies race against time to prevent countless deaths. We have the technology to make water safe, but we are...
PR Newswire
02/10/2025

XenoSTART and Minerva Imaging Expand Partnership to Deliver Integrated…

Radiopharmaceuticals are one of the fastest-growing areas in oncology, redefining how we treat cancer by precisely targeting tumors while sparing healthy tissue. In metastatic prostate cancer, these therapies are already changing standards of care and are now being explored in earlier disease stages and across other high-burden indications such as breast and neuroendocrine tumors. This expansion is driving an urgent need for robust, translational platforms that can shorten timelines and de-risk…
PR Newswire
02/10/2025

ERS 2025: BMC Showcases Innovation, Collaboration and a Future of Better…

At the BMC-sponsored Skills Lab: The Future of CPAP Monitoring – What Needs to Change Today? leading experts called for a shift beyond the traditional "4 hours/night" compliance metric. At the BMC-sponsoredSkills Lab: The Future of CPAP Monitoring – What Needs to Change Today?leading experts called for a shift beyond the traditional"4 hours/night"compliance metric. The session drew a nearly full room and sparked wide discussions across the ERS community, underscoring the…
PR Newswire
02/10/2025

AAVantgarde Announces FDA Orphan Drug Designation and UK CTA approval for…

AAVB-039 addresses the root cause of the disease, benefitting patients with any ABCA4 mutationAAVB-039 is currently being assessed in the CELESTE interventional clinical trial and we continue recruiting in our STELLA observational studyMILAN, Oct.02, 2025(GLOBE NEWSWIRE) --AAVantgarde Bio(AAVantgarde), a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted...
Nasdaq GlobeNewswire
02/10/2025

Personalized Nutrition Market worth $30.94 billion by 2030- Exclusive Report by…

Browse in-depth TOC on "Personalized Nutrition Market" Browse in-depth TOC on "Personalized Nutrition Market" 100 – Tables 70 – Figures 250 – Pages Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=249208030 Within product segment, digital tools and platforms to capture significant market share Digital tools and platforms are becoming the fastest-growing product segment in personalized nutrition, driven by scalable, data-centric, and...
PR Newswire
02/10/2025

ExQor Technologies Announces Advancement Toward Clinical Trials for Brain…

ExQor Technologies, a Boston MA based biotechnology company, is preparing for clinical trials for its proprietary brain regenerative medicine platform targeting Alzheimer's disease. Current Alzheimer's therapeutics are limited to slowing cognitive decline, but the company's preclinical data demonstrates something fundamentally different – the ability to reverse brain damage and promote regeneration. An additional trial is planned for frontotemporal dementia, while exploring other conditions…
PR Newswire
02/10/2025
Altri  Comunicati